Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$2.31 -10.3%	$2.47	$1.60 ▼ $17.55	$69.57M	1.93	402,401 shs	720,989 shs
CLDI Calidi Biotherapeutics	$0.23 -0.3%	$0.39	$0.20 ▼ $3.89	$7.28M	1.07	1.00 million shs	1.05 million shs
QNCX Quince Therapeutics	$1.50 -6.3%	$1.13	$0.51 ▼ $2.45	$72.75M	0.8	303,502 shs	206,275 shs
UNCY Unicycive Therapeutics	$5.94 -4.3%	$6.37	$2.02 ▼ $11.00	$78.50M	2.01	230,079 shs	841,683 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-10.83%	+1.99%	-19.69%	0.00%	-76.86%
CLDI Calidi Biotherapeutics	-0.26%	-22.37%	-42.92%	-64.77%	+22,899,900.00%
QNCX Quince Therapeutics	-6.25%	+10.29%	+47.06%	+11.11%	+113.83%
UNCY Unicycive Therapeutics	-4.35%	-11.01%	+0.49%	-3.26%	+23.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	1.4777 of 5 stars	3.3	1.0	0.6	0.8	1.3
CLDI Calidi Biotherapeutics	1.6321 of 5 stars	3.5	3.0	0.6	0.0	0.6
QNCX Quince Therapeutics	3.5787 of 5 stars	3.6	5.0	3.4	1.7	0.6
UNCY Unicycive Therapeutics	3.5962 of 5 stars	3.8	5.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	268.76% Upside
CLDI Calidi Biotherapeutics	3.00	Buy	$10.00	4,266.81% Upside
QNCX Quince Therapeutics	3.29	Buy	$8.00	433.33% Upside
UNCY Unicycive Therapeutics	3.50	Strong Buy	$60.00	910.10% Upside

Current Analyst Ratings Breakdown

Latest CLDI, UNCY, ANRO, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/4/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/11/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
4/1/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $75.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
CLDI Calidi Biotherapeutics	$50K	145.61	N/A	N/A	($2.32) per share	-0.10
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.69 per share	N/A
UNCY Unicycive Therapeutics	$680K	110.41	N/A	N/A	$0.72 per share	8.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.34	N/A	N/A	N/A	N/A	-39.35%	-33.86%	8/12/2025 (Estimated)
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
QNCX Quince Therapeutics	-$56.83M	-$1.39	N/A	N/A	N/A	N/A	-117.52%	-34.22%	8/12/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest CLDI, UNCY, ANRO, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$1.40	-$0.50	+$0.90	-$0.05	N/A	N/A
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/13/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A
3/27/2025	Q4 2024	UNCY Unicycive Therapeutics	-$1.30	-$2.60	-$1.30	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.15	22.53	22.53
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
QNCX Quince Therapeutics	0.82	4.05	4.05
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CLDI Calidi Biotherapeutics	12.53%
QNCX Quince Therapeutics	30.75%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.13%
CLDI Calidi Biotherapeutics	6.70%
QNCX Quince Therapeutics	20.30%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	24.06 million	N/A
CLDI Calidi Biotherapeutics	38	31.79 million	20.04 million	N/A
QNCX Quince Therapeutics	60	45.47 million	36.24 million	Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

CLDI, UNCY, ANRO, and QNCX Headlines

Recent News About These Companies

Unicycive Therapeutics Inc News (UNCY) - Investing.com

June 24 at 8:01 PM | investing.com

Unicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down - Time to Sell?

June 20, 2025 | marketbeat.com

Unicycive Therapeutics Inc trading halted, news pending

June 18, 2025 | msn.com

Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing

June 18, 2025 | investing.com

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

June 17, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in May

June 15, 2025 | marketbeat.com

UNCY Q3 EPS Forecast Raised by Brookline Capital Management

June 12, 2025 | marketbeat.com

Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

June 11, 2025 | theglobeandmail.com

Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m

June 11, 2025 | finance.yahoo.com

Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug Application

June 10, 2025 | marketwatch.com

Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues

June 10, 2025 | investing.com

Unicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025

June 10, 2025 | quiverquant.comQ

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 10, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short Interest

June 3, 2025 | marketbeat.com

What is HC Wainwright's Estimate for UNCY Q2 Earnings?

May 30, 2025 | marketbeat.com

Q4 Earnings Estimate for UNCY Issued By HC Wainwright

May 29, 2025 | marketbeat.com

Unicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC Wainwright

May 28, 2025 | marketbeat.com

Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences

May 22, 2025 | quiverquant.comQ

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDI, UNCY, ANRO, and QNCX Company Descriptions

Alto Neuroscience NYSE:ANRO

$2.31 -0.27 (-10.31%)

Closing price 06/26/2025 03:58 PM Eastern

Extended Trading

$2.32 +0.02 (+0.82%)

As of 06/26/2025 07:59 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Calidi Biotherapeutics NYSE:CLDI

$0.23 0.00 (-0.26%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.23 0.00 (-0.87%)

As of 06/26/2025 08:00 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Quince Therapeutics NASDAQ:QNCX

$1.50 -0.10 (-6.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.50 0.00 (0.00%)

As of 06/26/2025 07:21 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Unicycive Therapeutics NASDAQ:UNCY

$5.94 -0.27 (-4.35%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$6.02 +0.09 (+1.43%)

As of 06/26/2025 07:57 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time